Shanghai KingMed Diagnostics Co., Ltd.

Shanghai KingMed was established in 2011 and has obtained quality accreditation under dual international standards (ISO15189 and CAP). Shanghai KingMed is committed to integrating high-quality medical laboratory resources from the group and the local region, providing high-quality third-party medical laboratory and pathological diagnosis services to Shanghai and even the Yangtze River Delta region, fulfilling the original aspiration of KingMed Diagnostics to "help clinical doctors treat diseases well." Shanghai KingMed has always regarded serving clinical needs as the core of its business development, committed to clinical and disease-oriented promotion of effective communication and exchange between medical laboratory, pathological diagnosis services, and clinical medicine. With the development approach of multidisciplinary advancement and integration of multiple technological platforms, under the group's comprehensive and complete laboratory diagnostic technology system, it has built an industry-complete laboratory testing technology platform, including NGS/Sanger sequencing platforms, PCR platforms, fluorescence in situ hybridization platforms, flow cytometry platforms, pathology platforms, cytogenetics platforms, mass spectrometry chromatography platforms, biochemical luminescence platforms, immunoassay platforms, microbiology platforms, etc., covering mainstream technology fields from routine to high-end, providing clinical and patients with diagnostic services for full disease course management, full life cycle, and full disease coverage.